AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
VJHemOnc Podcast
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
Oct 1, 2020
Experts discuss recent updates in CAR-T and cellular therapy, including T cell engineering, CRISPR gene disruption, mesenchymal stem cells for COVID-19 pneumonia, and CAR-T cell therapy in challenging patient populations. They also analyze studies on CAR-T cell therapy, comparing management of toxicities, eligibility criteria, and durable responses. Additionally, they explore a comparison study between exocaptogen, CIBMTR, and T-stinlucil, and the potential of gene-edited effector cell therapy.
20:15
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Advancements in CAR-T and cellular therapy include the use of mesenchymal stem cells for graft versus host disease and potential application in COVID-19 inflammatory disease.
- Gene-edited effector cell therapy offers the potential to improve T-cell therapies by enhancing potency and creating off-the-shelf T-cells without graft-versus-host disease risk.
Deep dives
Advancements in Cellular Therapy for Hematological Malignancies
The podcast episode explores recent updates in CAR-T and cellular therapy for hematological malignancies. The first discussion focuses on the engineering of T cells and the use of mesenchymal stem cells for treating graft versus host disease (GVHD). The efficacy of CAR-T cell therapy and the use of CRISPR to disrupt genes are highlighted. Additionally, the potential application of mesenchymal stem cells in COVID-19 inflammatory disease is discussed. The second part of the podcast delves into CAR-T cell therapy for multiple myeloma, highlighting studies such as Karma, Cartitude 1, and Evolve that demonstrate high response rates and durable remission durations in a refractory patient population. Lastly, the podcast covers key clinical trials involving CAR-T cell therapy for refractory-diffuse large B-cell lymphoma, including Zuma1, Juliet, and Transcend studies, which show comparable durable responses and acceptable toxicity profiles.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode